Brainstorm Cell Therapeutics Inc (BCLI) - Total Liabilities
Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has total liabilities worth $50.00K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Brainstorm Cell Therapeutics Inc operating cash flow efficiency to assess how effectively this company generates cash.
Brainstorm Cell Therapeutics Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how Brainstorm Cell Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check BCLI financial resilience to evaluate the company's liquid asset resilience ratio.
Brainstorm Cell Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sintex Plastics Technology Limited
NSE:SPTL
|
India | Rs206.50 Million |
|
Dr. Martens PLC
LSE:DOCS
|
UK | GBX536.30 Million |
|
Anmol India Limited
NSE:ANMOL
|
India | Rs3.12 Billion |
|
FUTURE METALS NL
F:3R10
|
Germany | €381.80K |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
India | Rs440.20 Million |
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Brainstorm Cell Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Brainstorm Cell Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Brainstorm Cell Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Brainstorm Cell Therapeutics Inc (2001–2024)
The table below shows the annual total liabilities of Brainstorm Cell Therapeutics Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.60 Million | +5.85% |
| 2023-12-31 | $9.07 Million | -20.93% |
| 2022-12-31 | $11.47 Million | +15.41% |
| 2021-12-31 | $9.94 Million | -37.10% |
| 2020-12-31 | $15.79 Million | -15.79% |
| 2019-12-31 | $18.76 Million | +201.95% |
| 2018-12-31 | $6.21 Million | +12.07% |
| 2017-12-31 | $5.54 Million | +541.55% |
| 2016-12-31 | $864.00K | -70.73% |
| 2015-12-31 | $2.95 Million | -8.78% |
| 2014-12-31 | $3.24 Million | +62.86% |
| 2013-12-31 | $1.99 Million | +71.89% |
| 2012-12-31 | $1.16 Million | -7.96% |
| 2011-12-31 | $1.26 Million | -18.86% |
| 2010-12-31 | $1.55 Million | -38.08% |
| 2009-12-31 | $2.50 Million | -15.28% |
| 2008-12-31 | $2.95 Million | -15.95% |
| 2007-12-31 | $3.51 Million | +38.33% |
| 2006-12-31 | $2.54 Million | -71.06% |
| 2005-12-31 | $8.77 Million | +4913.06% |
| 2004-12-31 | $174.95K | +267.03% |
| 2003-12-31 | $47.67K | +89.70% |
| 2002-12-31 | $25.13K | +118.69% |
| 2001-12-31 | $11.49K | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modula… Read more